Neo Ivy Capital Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-186,172
| Closed | -$2.69M | – | 407 |
|
|
2026
Q1 | $2.69M | Sell |
186,172
-234,103
| -56% | -$3.36M | 0.71% | 39 |
|
|
2025
Q4 | $5.98M | Buy |
420,275
+371,011
| +753% | +$3.64M | 0.95% | 27 |
|
|
2025
Q3 | $388K | Buy |
+49,264
| New | +$351K | 0.09% | 263 |
|
|
2025
Q1 | – | Sell |
-395,745
| Closed | -$3.73M | – | 333 |
|
|
2024
Q4 | $3.73M | Buy |
395,745
+329,959
| +502% | +$3.43M | 0.75% | 27 |
|
|
2024
Q3 | $702K | Buy |
+65,786
| New | +$716K | 0.23% | 172 |
|
|
2023
Q4 | – | Sell |
-6,244
| Closed | -$76K | – | 349 |
|
|
2023
Q3 | $76K | Sell |
6,244
-21,074
| -77% | -$272K | 0.03% | 265 |
|
|
2023
Q2 | $343K | Buy |
+27,318
| New | +$324K | 0.18% | 185 |
|
|
2022
Q4 | $121K | Buy |
+9,882
| New | +$111K | 0.08% | 254 |
|
|
2022
Q2 | – | Sell |
-3,318
| Closed | -$32K | – | 481 |
|
|
2022
Q1 | $32K | Buy |
3,318
+1,864
| +128% | +$17.5K | 0.03% | 401 |
|
|
2021
Q4 | $17K | Sell |
1,454
-1,618
| -53% | -$18K | 0.02% | 366 |
|
|
2021
Q3 | $46K | Sell |
3,072
-33,522
| -92% | -$343K | 0.05% | 330 |
|
|
2021
Q2 | $353K | Buy |
+36,594
| New | +$357K | 0.36% | 108 |
|
|
2021
Q1 | – | Sell |
-6,178
| Closed | -$143K | – | 523 |
|
|
2020
Q4 | $143K | Buy |
6,178
+3,202
| +108% | +$65.5K | 0.16% | 203 |
|
|
2020
Q3 | $42K | Sell |
2,976
-96
| -3% | -$1.4K | 0.04% | 376 |
|
|
2020
Q2 | $46K | Sell |
3,072
-12,423
| -80% | -$151K | 0.05% | 330 |
|
|
2020
Q1 | $143K | Buy |
15,495
+4,147
| +37% | +$39.4K | 0.23% | 174 |
|
|
2019
Q4 | $111K | Buy |
+11,348
| New | +$104K | 0.13% | 186 |
|
|
2019
Q3 | – | Sell |
-4,448
| Closed | -$56K | – | 324 |
|
|
2019
Q2 | $56K | Buy |
4,448
+252
| +6% | +$3.2K | 0.03% | 230 |
|
|
2019
Q1 | $57K | Buy |
+4,196
| New | +$51.3K | 0.03% | 249 |
|
Other funds holding FOLD
Neo Ivy Capital Management's FOLD Position: Q2 2026 in Review
Neo Ivy Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 186,172 shares — an estimated $2.69M sold.
Neo Ivy Capital Management first reported a position in FOLD in Q1 2019 and held it in 19 quarters. The position peaked at $5.98M in Q4 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Neo Ivy Capital Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Neo Ivy Capital Management sold 186,172 Amicus Therapeutics shares in Q2 2026, an estimated $2.69M.
- Neo Ivy Capital Management first reported a position in Amicus Therapeutics in Q1 2019 and held it in 19 quarters.
- Neo Ivy Capital Management's Amicus Therapeutics position peaked at $5.98M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.